The Telegraph: Rare disease drug firm Healx raises $56 million

 

Healx, a startup that seeks breakthroughs for rare diseases through artificial intelligence, secured $56 million in Series B financing, led by venture capital firm Atomico. The funding will be used to develop Healx’s therapeutic pipeline and to launch its global Rare Treatment Accelerator programme. Healx was previously on the Accelerate Cambridge programme at the Entrepreneurship Centre. (subs)

Read the full article [telegraph.co.uk]